Incorporated in 1998, CutisPharma developed a leading position within the niche market of prescription compounding with the innovative FI℞ST® Unit-of-Use Kit portfolio of products. The FI℞ST® concept revolutionized compounding, providing pharmacists with a convenient, standardized, high quality alternative to traditional compounding for a select portfolio of medications. The FI℞ST® franchise grew from a portfolio of two product offerings over 16 years ago to now a total of 24 different products with extensive usage across all national pharmacy chains, hospital/long term care pharmacies, and independent pharmacies.
In 2014, the Company embarked on several significant initiatives to transition the business from its historical base in the pharmacy compounding market toward development and commercialization of FDA-approved drugs. In the spring of 2014, we significantly expanded our operating infrastructure and capabilities with a move into a new state-of-the-art corporate headquarters that includes facilities for warehousing, distribution and manufacturing. In March of 2016, we celebrated the opening of our state-of-the art manufacturing center at our Wilmington, Massachusetts facility, which will support our NDA pipeline activities. In April of 2016, the Company announced the initiation of a development and commercialization partnership with Dr. Reddy’s Laboratories, which has expanded our NDA portfolio and will accelerate our progress towards regulatory filings for FDA approval.
Our transformation has taken us a long way from our historical roots as a supplier of compounding kits to pharmacists towards the creation of a fully-integrated specialty pharmaceutical company with the capability to develop, manufacture and commercialize a portfolio of new drugs; however, our commitment to science, quality, and improvement of patient health remains our core mission and is our guiding principle for our future growth.
©2018 CutisPharma, Inc.
FI℞ST® and the FI℞ST® logo are registered
trademarks of CutisPharma, Inc.